De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
West Pharmaceutical Services Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
West Pharmaceutical Services heeft een totaal eigen vermogen van $2.6B en een totale schuld van $205.8M, wat de schuld-eigenvermogensverhouding op 8% brengt. De totale activa en totale passiva bedragen respectievelijk $3.5B en $912.6M. De EBIT West Pharmaceutical Services is $610.7M waardoor de rentedekking -28.8 is. Het heeft contanten en kortetermijnbeleggingen van $446.2M.
Belangrijke informatie
8.0%
Verhouding schuld/eigen vermogen
US$205.80m
Schuld
| Rente dekkingsratio | -28.8x |
| Contant | US$446.20m |
| Aandelen | US$2.58b |
| Totaal verplichtingen | US$912.60m |
| Totaal activa | US$3.49b |
Recente financiële gezondheidsupdates
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31Recent updates
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $1.5B ) WST } overtreffen de korte termijn passiva ( $633.7M ).
Langlopende schulden: De kortetermijnactiva WST ( $1.5B ) overtreffen de langetermijnschulden ( $278.9M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: WST heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van WST is de afgelopen 5 jaar gedaald van 13.6% naar 8%.
Schuldendekking: De schuld van WST wordt goed gedekt door de operationele kasstroom ( 365.6% ).
Rentedekking: WST verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.